Lipid lowering in the patients with prediabetes/metabolic syndrome: What is the evidence?

Current Opinion in Lipidology

Volumn 19, Issue 6, 2008, Pages 585-591

  Steiner, George ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Drugs; Lipoproteins; Metabolic syndrome

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; FLUSHING; GASTRITIS; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY INJURY; LIFESTYLE MODIFICATION; LIPOPROTEIN DEFICIENCY; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; HUMANS; LIPID METABOLISM; LIPOPROTEINS; PHARMACEUTICAL PREPARATIONS; PREDIABETIC STATE; RISK FACTORS;

EID: 56549099364     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283189c2b     Document Type: Review

References (78)

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes and mellitus [publication no. WHO/NCD/NCS/99.2]. Geneva: World Health Organization; 1999.
2. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16:442-443.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
4. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9:237-252.
5. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059-1062.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
7. Alberti KGMM. The Screening and diagnosis of prediabetes: where are we headed? Diabetes Obes Metab 2007; 9 (Suppl 1):12-16.
8. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98:398-404.
9. Ballantyne CM, Hoogeveen RC, McNeill AM, et al. Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC study. Int J Obes 2008; 32:S21-S24. An American community study of the cardiovascular risks of both diabetes and the metabolic syndrome.
10. Eddy DM, Schlessinger L, Heikes K. The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes 2008; 32:S5-S10. A review of the cardiovascular implications of the metabolic syndrome.
11. Wang J, Ruotsalainen S, Moilanen L, et al. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly nondiabetic Finns. Eur Heart J 2007; 28:857-864. The long-term cardiovascular implications of the metabolic syndrome.
12. Assmann G, Schulte1 H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes 2008; 32:S11-S16. A summary of a large prospective examination of coronary risk.
13. Alberti KGMM. The metabolic syndrome: setting the scene. The pros. Diabetes Vasc Dis Res 2007; 4 (Suppl 2):S1-S3. This is a recent summary of the reasons to consider the metabolic syndrome as a distinct entity.
14. Sattar N. The metabolic syndrome: setting the scene. The cons. Diabetes Vasc Dis Res 2007; 4 (Suppl 2):S4-6. This is a recent summary of the reasons to reject the metabolic syndrome as a distinct entity.
15. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104:1108-1113.
16. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113:1556-1563.
17. El Harchaoui K, van der Steeg WA, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC Norfolk prospective population study. J Am Coll Cardiol 2007; 49:547-553. A nested case-control study with an average follow-up of 6 years showing that both LDL particle number and LDL particle size predict coronary disease over and above that of the Framingham risk score alone.
18. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003; 88:4525-4532.
19. Elovson J, Chatterton JE, Bell GT, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988; 29:1461-1473.
20. Chapman MJ, Laplaud PM, Luc G, et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 1988; 29:442-458.
21. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361:777-780.
22. Kastelein JJP, van der Steeg WA, Holme I, et al., for the TNT and IDEAL Study Groups. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117:3002-3009. This study adds data from two studies that support the use of apoB and apoA measurement as strong predictors of coronary risk.
23. John D, Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51:1512-1524. This is a review of the information that supports the guidelines and targets suggested jointly by the American Diabetes Association and the American College of Cardiology.
24. Liu J, Sempos C, Donahue R, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005; 28:1916-1921.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
26. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther 2007; 14:567-580.
27. Ginsberg HN. Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006; 91:383-392.
28. Darkes MJ, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs 2003; 3:67-76.
29. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008; 6:447-470.
30. Kastelein JJ, Akdim F, Stroes ES, et al., and the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-1443. This study has raised many questions about the importance of cholesterol reduction, about the role of adding ezetimibe to simvastatin and about the use of carotid IMT as a surrogate marker of coronary disease. However, the lack of any increased benefit on carotid IMT when ezetimibe was added to simvastatin may only reflect the nature of the population studies.
31. Shepherd J, Betteridge J, Van Gaal L, European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005; 21:665-682.
32. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1246-1255.
33. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101:625-630.
34. Bays HE. Safety of niacin and simvastatin combination therapy safety considerations with niacin therapy. Am J Cardiol 2008; 101:3B-8B. A review of the safety and adverse effects of niacin alone and in combination with a statin. This review not only describes niacin's adverse effects, but also indicates that they are not different if the drug is used alone or in combination with simvastatin.
35. Poynten AM, Gan SK, Kriketos AD, et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metab Clin Exp 2003; 52:699-704.
36. Chang AM, Smith MJ, Galecki AT, et al. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J Clin Endocrinol Metab 2006; 91:3303-3309.
37. Westphal S, Borucki K, Taneva E, et al. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007; 193:361-365. This is the only assessment reported to date of insulin resistance in people taking an extended release preparation of niacin. It shows, using HOMA, that this form of niacin, just like crystalline niacin, increases insulin resistance.
38. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002; 162:1568-1576.
39. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT Study: a randomized trial: Arterial Disease Multiple Intervention Trial. JAMA 2000; 284:1263-1270.
40. Zambon A, Cusi K. The role of fenofibrate in clinical practice. Diab Vasc Dis Res 2007; 4 (Suppl 3):S15-S20.
41. Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004; 93:848-853.
42. Bonaa KH, Njolstad I, Ueland PM, et al., for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction [see comment]. N Engl J Med 2006; 354:1578-1588.
43. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92:536-541.
44. Keech A, Simes RJ, Barter P, et al., for FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
45. Ansquer JC, Dalton RN, Caussé E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008; 51:904-913. There is ongoing uncertainty about the cause and implications of the increase in creatinine seen in fibrate-treated people. This study examines renal function in fenofibrate-treated individuals with normal renal function.
46. Ansquer JC, Foucher C, Rattier S, et al., DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2006; 45:485-493.
47. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95:120-122.
48. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006; 5:145-156.
49. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on the interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042-1051.
50. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on the metabolism of statins in human hepatocytes. Drug Metab Dispos 2006; 34:191-197.
51. Shah PK. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J 2007; 28:5-12. This study reviews the physiology of CETP and the potential utility of its inhibition as a strategy to reduce coronary risk.
52. Barter PJ, Caulfield M, Eriksson M, et al., for the ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. The only morbidity and mortality study of a CETP inhibitor (torcetrapib) added to atorvastatin vs. atorvastatin alone to date was stopped prematurely because of an, as yet unexplained, increase in mortality in the former group.
53. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomised phase II dose response study. Circulation 2002; 105:2159-2165.
54. Vergeer M, Kastelein JJ. Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat Clin Pract Cardiovasc Med 2008; 5:302-303.
55. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiolo 2005; 46:1855-1862.
56. Collins R, Armitage J, Parish S, et al., Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
57. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364:685-696.
58. Cholesterol Treatment Trialists' Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 2008; 371:117-125. This meta-analysis supports the importance of cholesterol reduction with statins in those with diabetes.
59. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046-3051.
60. Deedwania P, Barter P, Carmena R, et al., for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368:919-928.
61. Grundy SM, Cleeman JI, Merz CN, et al., Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-732.
62. Committee of Principal Investigators. A cooperative trial in the prevention of ischemic heart disease using clofibrate. Br Heart J 1978; 40:1069-1118.
63. Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; ii:600-604.
64. Research committee of the Scottish Society of Physicians. Ischemic heart disease: a secondary prevention trial using clofibrate. Br Med J 1971; 4:775-784.
65. Group of physicians of the Newcastle upon Tyne region. Trial of clofibrate in the treatment of ischemic heart disease. Br Med J 1971; 4:767-775.
66. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia - safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
67. Manninen V, Koskinen P, Manttari M, et al. Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study. Am J Cardiol 1990; 66:24A-27A.
68. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21-27.
69. Robins SJ, Collins D, Wittes JT, et al., for the VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT - a randomized controlled trial. JAMA 2001; 285:1585-1591.
70. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15:820-825.
71. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21:641-648.
72. Anonymous. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-910.
73. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162:2597-2604.
74. Robins SJ, Rubins HB, Faas FH, et al. Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003; 26:1513-1517.
75. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Internal Med 2005; 165:1154-1160.
76. ACCORD Study Group. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99:21i-33i.
77. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358:2630-2633. The intensive glycemic control group of the ACCORD study was stopped prematurely because of an increased mortality rate. The reasons for this are not known, particularly as such an increase was not observed in ADVANCE. This study reports on the intensive glycemic control groups of both studies.
78. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The SANDS Randomized Trial. JAMA 2008; 299:1678-1689. This study indicates the complexities in establishing targets. It treated native Americans with diabetes to their targets for both BP and LDL-C and found that although, in the intensively treated group, there was regression of ultrasonographically evaluated carotid disease and greater decrease left ventricular mass, there was no difference in cardiovascular endpoints.